Brooklyn Investment Group Invests $66,000 in Illumina, Inc. (NASDAQ:ILMN)

Brooklyn Investment Group bought a new stake in Illumina, Inc. (NASDAQ:ILMN) in the third quarter, HoldingsChannel reports. The firm bought 507 shares of the life sciences company’s stock, valued at approximately $66,000.

Several other hedge funds also recently made changes to their positions in ILMN. Primecap Management Co. CA lifted its position in Illumina by 462.5% during the 2nd quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock valued at $253,514,000 after acquiring an additional 1,997,010 shares during the period. Millennium Management LLC boosted its position in shares of Illumina by 305.0% in the 2nd quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock worth $155,067,000 after purchasing an additional 1,118,747 shares in the last quarter. Marshall Wace LLP purchased a new position in Illumina during the second quarter valued at $77,628,000. Massachusetts Financial Services Co. MA boosted its holdings in Illumina by 148.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock worth $137,735,000 after acquiring an additional 631,294 shares in the last quarter. Finally, Federated Hermes Inc. grew its stake in shares of Illumina by 511.7% in the second quarter. Federated Hermes Inc. now owns 530,439 shares of the life sciences company’s stock worth $55,367,000 after acquiring an additional 443,720 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Trading Up 1.0 %

Shares of ILMN stock opened at $144.36 on Friday. Illumina, Inc. has a twelve month low of $93.51 and a twelve month high of $156.66. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. The business’s 50 day moving average is $141.62 and its two-hundred day moving average is $125.66. The company has a market capitalization of $22.90 billion, a P/E ratio of -14.49 and a beta of 1.13.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter in the prior year, the firm earned $0.33 EPS. Illumina’s quarterly revenue was down 3.5% on a year-over-year basis. Equities analysts forecast that Illumina, Inc. will post 4.11 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on ILMN shares. Scotiabank dropped their price target on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a research note on Thursday, August 15th. Robert W. Baird lifted their price objective on Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a research report on Thursday, October 17th. Argus upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $150.00 price target for the company in a research report on Wednesday, August 28th. Finally, Daiwa America raised Illumina to a “strong-buy” rating in a report on Friday, August 16th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and an average target price of $164.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.